HMGCR and nasopharyngeal carcinoma: Another potential drug tested in preclinical models of NPC is lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzime A (HMG-CoA) reductase, which was evaluated for its ability to induce differentiation of OLs derived from a mouse model of NPC; the results showed that it inhibited cholesterol synthesis, reduced its accumulation in endo-lysosomes, and increased the maturation of NPC OLs [49].